Advertisement
Screener

Disc Medicine, Inc. (IRON) Investing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Disc Medicine, Inc. Investing Cash Flow

Disc Medicine, Inc. (IRON) reported Investing Cash Flow of $79.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.

Financial Statements › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-07-30

  • Disc Medicine, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $21.63M, a 58.16% decline year-over-year.
  • Disc Medicine, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $58.31M.
  • Disc Medicine, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$222.89M.
  • Disc Medicine, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $49.54M.
  • Disc Medicine, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$394.30M.
  • Disc Medicine, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$292.33M.
  • Disc Medicine, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$89.00K.
  • Disc Medicine, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$151.00K.
Period endNet Cash Provided by (Used in) Investing Activities 3 monthNet Cash Provided by (Used in) Investing Activities 6 monthNet Cash Provided by (Used in) Investing Activities 9 monthNet Cash Provided by (Used in) Investing Activities 9 month as first filedNet Cash Provided by (Used in) Investing Activities 12 monthNet Cash Provided by (Used in) Investing Activities 12 month as first filed
2026-06-30$21.63M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30
$79.94M
10-Q · filed 2026-07-30
-$142.96M
derived: sum of 3 quarters · filed 2026-07-30
-$93.42M
derived: sum of 4 quarters · filed 2026-07-30
2026-03-31$58.31M
10-Q · filed 2026-05-05
-$164.59M
derived: sum of 2 quarters · filed 2026-05-05
-$115.05M
derived: sum of 3 quarters · filed 2026-05-05
-$63.36M
derived: sum of 4 quarters · filed 2026-07-30
2025-12-31-$222.89M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$173.35M
derived: sum of 2 quarters · filed 2026-02-26
-$121.67M
derived: sum of 3 quarters · filed 2026-07-30
-$394.30M
10-K · filed 2026-02-26
2025-09-30$49.54M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$101.23M
derived: sum of 2 quarters · filed 2026-07-30
-$171.41M
10-Q · filed 2025-11-06
-$172.83M
derived: sum of 4 quarters · filed 2026-07-30
2025-06-30$51.69M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30
-$220.94M
10-Q · filed 2026-07-30
-$222.37M
derived: sum of 3 quarters · filed 2026-07-30
-$293.46M
derived: sum of 4 quarters · filed 2026-07-30
2025-03-31-$272.63M
10-Q · filed 2026-05-05
-$274.06M
derived: sum of 2 quarters · filed 2026-05-05
-$345.15M
derived: sum of 3 quarters · filed 2026-05-05
-$564.90M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31-$1.43M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$72.52M
derived: sum of 2 quarters · filed 2026-02-26
-$292.26M
derived: sum of 3 quarters · filed 2026-02-26
-$292.33M
10-K · filed 2026-02-26
2024-09-30-$71.09M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$290.84M
derived: sum of 2 quarters · filed 2025-11-06
-$290.91M
10-Q · filed 2025-11-06
-$290.91M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30-$219.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$219.82M
10-Q · filed 2025-08-07
-$219.82M
derived: sum of 3 quarters · filed 2026-02-26
-$219.86M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31-$67.00K
10-Q · filed 2025-05-07
-$70.00K
derived: sum of 2 quarters · filed 2026-02-26
-$115.00K
derived: sum of 3 quarters · filed 2026-02-26
-$127.00K
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31-$3.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$48.00K
derived: sum of 2 quarters · filed 2026-02-26
-$60.00K
derived: sum of 3 quarters · filed 2026-02-26
-$89.00K
10-K · filed 2026-02-26
2023-09-30-$45.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
-$57.00K
derived: sum of 2 quarters · filed 2024-11-12
-$86.00K
10-Q · filed 2024-11-12
-$98.00K
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30-$12.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
-$41.00K
10-Q · filed 2024-08-08
-$53.00K
derived: sum of 3 quarters · filed 2024-08-08
-$72.00K
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$29.00K
10-Q · filed 2024-05-09
-$41.00K
derived: sum of 2 quarters · filed 2024-05-09
-$60.00K
derived: sum of 3 quarters · filed 2024-05-09
-$80.00K
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31-$12.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21
-$31.00K
derived: sum of 2 quarters · filed 2024-03-21
-$51.00K
derived: sum of 3 quarters · filed 2024-03-21
-$151.00K
10-K · filed 2024-03-21
2022-09-30-$19.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
-$39.00K
derived: sum of 2 quarters · filed 2023-11-09
-$139.00K
10-Q · filed 2023-11-09
$0.00
10-Q · filed 2022-11-10
-$146.00K
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30-$20.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11
-$120.00K
10-Q · filed 2023-08-11
-$127.00K
derived: sum of 3 quarters · filed 2023-08-11
2022-03-31-$100.00K
10-Q · filed 2023-05-15
-$107.00K
derived: sum of 2 quarters · filed 2023-05-15
2021-12-31-$7.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31
-$68.00K
10-K · filed 2023-03-31
$344.00K
10-K · filed 2022-03-10
2021-09-30-$61.00K
10-Q · filed 2022-11-10
2020-12-31$0.00
derived: 10-K 6 month − 10-Q 3 month · filed 2021-03-29
-$120.75M
10-K · filed 2021-03-29
-$22.00K
10-K · filed 2022-03-10
2020-09-30-$120.75M
10-Q · filed 2020-11-12
-$22.00K
10-Q · filed 2021-11-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Immunome Inc. (IMNM)United States$2.538B-9.45
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82